Application of Mid-Pancreatectomy with End-to-End Anastomosis in Pancreatic Benign Tumors
February 9th, 2024
The present protocol describes the application of mid-pancreatectomy combined with end-to-end anastomosis in the surgical treatment of pancreatic benign tumors, which presents a feasible solution for managing such tumors while concurrently preserving pancreatic function.
After making a vertical incision on the anesthetized patient, carefully explore the intraperitoneal organs and peritoneal surface to reveal a mass above the pancreas measuring approximately three centimeters by three centimeters. Using an ultrasonic knife, separate abdominal adhesions and excise a portion of omental tissue. Free the greater curvature side tissues of the gastroepiploic artery with the help of an ultrasonic knife.
Suspend the greater curvature of the stomach using clamps, and expose the pancreas. After intraoperative B ultrasound localization, use an ultrasonic scalpel to cut off one centimeter of normal pancreatic tissue from the edge of the pancreatic mass near the neck of the pancreas. Now, free the splenic artery and vein at the upper posterior of the pancreas with the help of an ultrasonic knife.
Then, free the connective tissue between the tail and body of the pancreas and the splenic vessels. Resect the pancreatic mass completely using an ultrasonic scalpel to remove the normal pancreatic tissue one centimeter proximal to the margin of the pancreatic mass. Place the stent tubes into the proximal and distal sides of the pancreas within the pancreatic ducts.
Suture the pancreatic tissue continuously using 4-0 Prolene and make an extended incision two centimeters below the navel to remove the pancreatic mass. Laparoscopic mid pancreatectomy combined with end-to-end anastomosis showed a decrease in drain amylase levels from 29, 300 units per liter on postoperative day one to 58.39 units per liter on postoperative day five. Venous blood analysis revealed a reduction in carcinoembryonic antigen levels from 5.8 nanograms per milliliter preoperatively to 2.28 nanograms per milliliter postoperatively.
Alpha-fetoprotein levels decreased from 30.53 nanograms per milliliter before surgery to 7.66 nanograms per milliliter after surgery.
Overview
This protocol outlines the surgical technique of mid-pancreatectomy combined with end-to-end anastomosis for treating pancreatic benign tumors. It emphasizes the preservation of pancreatic function while effectively managing the tumors.
Key Study Components
Area of Science
- Surgery
- Pancreatic health
- Oncology
Background
- Pancreatic benign tumors can pose significant health challenges.
- Traditional surgical methods may compromise pancreatic function.
- Innovative techniques are needed to improve patient outcomes.
- This study explores a combined surgical approach.
Purpose of Study
- To describe a surgical protocol for mid-pancreatectomy.
- To assess the feasibility of preserving pancreatic function.
- To provide a solution for managing pancreatic benign tumors.
Methods Used
- Vertical incision on the anesthetized patient.
- Exploration of intraperitoneal organs to locate the tumor.
- Use of an ultrasonic knife for tissue separation and excision.
- Intraoperative B ultrasound for localization of the mass.
Main Results
- Successful identification and excision of the pancreatic mass.
- Preservation of surrounding pancreatic tissue.
- Effective management of abdominal adhesions.
- Demonstration of the technique's feasibility.
Conclusions
- Mid-pancreatectomy with end-to-end anastomosis is a viable surgical option.
- This approach helps maintain pancreatic function.
- Further studies may validate long-term outcomes.
Frequently Asked Questions
Executive Industry Relevance
Mid-pancreatectomy with end-to-end anastomosis addresses the challenge of preserving pancreatic function during surgical management of benign pancreatic tumors. This technique reduces the risk of postoperative insufficiency and supports functional tissue retention, which is critical for translational research and preclinical modeling. Its procedural complexity and functional outcomes are directly relevant to biopharma teams developing disease-relevant models and evaluating surgical interventions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables creation of physiologically relevant preclinical models for pancreatic function studies.
- Supports mechanistic de-risking by preserving endocrine and exocrine tissue for downstream analysis.
- Facilitates functional validation of surgical interventions in benign tumor contexts.
Screening & Assay Development
- Provides a reproducible surgical protocol for generating consistent biological samples.
- Enables quantitative monitoring of biomarkers such as amylase and tumor markers post-surgery.
- Supports assay development for pancreatic function and tissue viability assessment.
Translational & Preclinical Research
- Aligns with disease-relevant system modeling by preserving native pancreatic pathways.
- Enables longitudinal monitoring of functional outcomes and biomarker continuity.
- Supports risk-adjusted evaluation of surgical innovations in preclinical settings.
Pipeline & Workflow Integration
This surgical method integrates into the discovery-to-preclinical continuum by enabling functional tissue preservation and quantitative biomarker tracking post-intervention.
- Discovery Biology: Supports hypothesis testing on pancreatic tissue preservation and function.
- Screening: Provides standardized outputs for biomarker and functional assay development.
- Analytics: Enables quantitative measurement of amylase, carcinoembryonic antigen, and alpha-fetoprotein for comparative studies.
- Translational Research: Facilitates continuity from surgical intervention to functional outcome assessment.
- Enterprise Reuse: Offers a reproducible protocol adaptable for various benign pancreatic tumor models.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence in functional tissue preservation and biomarker stability.
- Operational Value: Standardizes surgical and monitoring procedures for reproducibility.
- Strategic Value: Reduces late-stage biological risk by preserving critical pancreatic function.
- Portfolio Impact: Informs risk-adjusted prioritization of surgical and therapeutic strategies.
Implementation Considerations
- Requires surgical expertise in pancreatic tissue handling and anastomosis.
- Demands access to intraoperative imaging and quantitative biomarker analysis tools.
- Necessitates standardized postoperative monitoring protocols for function and biomarkers.
- Adaptation may be needed for different benign tumor types or anatomical variations.
- Complexity and risk profile require thorough preoperative evaluation and planning.
